keyword
MENU ▼
Read by QxMD icon Read
search

BK viremia

keyword
https://www.readbyqxmd.com/read/29679773/distinctive-infectious-complications-in-patients-with-central-nervous-system-lymphoma-undergoing-thiotepa-busulfan-and-cyclophosphamide-tbc-conditioned-autologous-stem-cell-transplantation
#1
Michael Scordo, Sejal M Morjaria, Eric R Littmann, Ankush Bhatia, Helen H Chung, Molly Maloy, Lisa M DeAngelis, Sergio A Giralt, Ying Taur, Craig S Sauter
We investigated the incidence of viral, fungal, bacterial, and parasitic infections observed in 57 patients with central nervous system lymphoma (CNSL) after TBC-ASCT and 79 patients with systemic NHL after traditional BEAM-ASCT. Twenty of 57 (35%) TBC-ASCT patients had detectable viremia with human herpesvirus 6 (HHV-6), cytomegalovirus (CMV), adenovirus (ADV), or BK virus (BKV), versus 9 of 79 (11%) BEAM-ASCT patients. Nine TBC-ASCT patients had clinically relevant viral infections (4 HHV-6, 2 CMV, 1 ADV, 2 BKV), versus 0 in the BEAM-ASCT group...
April 18, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29679772/efficacy-of-cidofovir-in-treatment-of-bk-virus-induced-hemorrhagic-cystitis-in-post-allogeneic-hematopoietic-cell-transplant-recipients
#2
Eric A Coomes, Amanda Jacques Wolfe, Fotios V Michelis, Dennis Dong-Hwong Kim, Santhosh Thyagu, Auro Viswabandya, Jeffrey H Lipton, Hans A Messner, Uday Deotare
BACKGROUND: BK virus associated hemorrhagic cystitis (BK-HC) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HCT), with incidence up to 70%. Cidofovir is an antiviral agent with growing evidence as a therapeutic intervention. OBJECTIVE: To assess the safety profile and efficacy of intravenous and intravesical cidofovir in allo-HCT patients with BK-HC. METHODS: Retrospective study of the allo-HCT cohort who received cidofovir for symptomatic BK-HC (hematuria with BK viruria or viremia) from January 2010 until March 2017 in a single transplant center in Ontario, Canada...
April 18, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29676018/conversion-from-tacrolimus-mycophenolate-mofetil-to-tacrolimus-mtor-immunosuppression-after-kidney-pancreas-transplantation-reduces-the-incidence-of-both-bk-and-cmv-viremia
#3
Richard J Knight, Edward A Graviss, Duc T Nguyen, Samantha A Kuten, Samir J Patel, Lillian Gaber, A Osama Gaber
BACKGROUND: We sought to determine if conversion from tacrolimus/mycophenolate mofetil (TAC-MMF) to tacrolimus/mTOR inhibitor (TAC-mTOR) immunosuppression would reduce the incidences of BK and CMV viremia after kidney/pancreas (KP) transplantation. METHODS: In this single center review, the TAC-mTOR cohort (n=39) was converted at one month post-transplant to an mTOR inhibitor and reduced dose tacrolimus. Outcomes were compared to a cohort of KP recipients (n=40) maintained on TAC-MMF...
April 19, 2018: Clinical Transplantation
https://www.readbyqxmd.com/read/29649002/jak1-2-inhibition-with-baricitinib-in-the-treatment-of-autoinflammatory-interferonopathies
#4
Gina A Montealegre Sanchez, Adam Reinhardt, Suzanne Ramsey, Helmut Wittkowski, Philip J Hashkes, Yackov Berkun, Susanne Schalm, Sara Murias, Jason A Dare, Diane Brown, Deborah L Stone, Ling Gao, Thomas Klausmeier, Dirk Foell, Adriana A de Jesus, Dawn C Chapelle, Hanna Kim, Samantha Dill, Robert Colbert, Laura Failla, Bahar Kost, Michelle O'Brien, James C Reynolds, Les R Folio, Katherine R Calvo, Scott M Paul, Nargues Weir, Alessandra Brofferio, Ariane Soldatos, Angélique Biancotto, Edward W Cowen, John G Digiovanna, Massimo Gadina, Andrew J Lipton, Colleen Hadigan, Steven M Holland, Joseph Fontana, Ahmad S Alawad, Rebecca J Brown, Kristina I Rother, Theo Heller, Kristina M Brooks, Parag Kumar, Stephen R Brooks, Meryl Waldman, Harsharan K Singh, Volker Nickeleit, Maria Silk, Apurva Prakash, Jonathan M Janes, Seza Ozen, Paul G Wakim, Paul A Brogan, William L Macias, Raphaela Goldbach-Mansky
BACKGROUND: Monogenic Interferon (IFN)-mediated autoinflammatory diseases present in infancy with systemic inflammation, an IFN-response-gene-signature (IRS), inflammatory organ damage and high mortality. We used the janus kinase (JAK) inhibitor baricitinib with IFN-blocking activity in vitro, to ameliorate disease. METHODS: Between October 2011 and February 2017, 10 patients with CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures), 4 with SAVI (Stimulator of IFN genes (STING)-associated vasculopathy with onset in infancy), and 4 patients with other interferonopathies were enrolled in an Expanded Access Program...
April 12, 2018: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29599935/bk-virus-associated-collecting-duct-carcinoma-of-the-renal-allograft-in-a-kidney-pancreas-allograft-recipient
#5
Myriam Dao, Adrien Pécriaux, Thomas Bessede, Antoine Dürrbach, Charlotte Mussini, Catherine Guettier, Sophie Ferlicot
BK polyomavirus (BKV) nephropathy is a major concern in renal transplantation. Its main consequence is graft loss, which occurs in more than 50% of the cases. De novo renal cell carcinoma in renal allograft is a very rare event. Most of these tumors are papillary or clear cell carcinomas. We report herein the first case of collecting duct carcinoma of the renal allograft in a kidney-pancreas allograft adult recipient. Collecting duct carcinoma occurs long after the cure of a BKV nephropathy. At this time, BKV viremia and viruria were negative as well as the immunostaining for SV40 in the non-tumor kidney...
March 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29579853/survival-and-evolution-of-renal-function-in-kidney-transplant-recipients-from-type-ii-asystolic-donations-a-single-center-experience
#6
N G Toapanta Gaibor, F M González-Roncero, M Cintra Cabrera, M Suñer Poblet, G Bernal Blanco, A Suarez Benjumea, M A Pérez-Valdivia, J J Egea-Guerrero, J L Rocha Castilla, M A Gentil Govantes
BACKGROUND: In recent years, stagnation in the number of kidneys from after brain-dead donors (DBD) has stimulated the use of non-heart beating donors (NHBDs). Herein we present our 5-year experience with type II Maastricht NHBDs in renal transplantation. METHODS: All patients (n = 50) in this study received type II Maastricht NHBD kidneys (March 2012 to February 2017), with a median follow-up of 33 months. RESULTS: Mean donor age was 39 ± 12 years, mean creatinine 1...
March 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29579827/epidemiologic-study-and-genotyping-of-bk-virus-in-renal-transplant-recipients
#7
M Cobos, L Aquilia, E Garay, S Ochiuzzi, S Alvarez, D Flores, C Raimondi
BK virus (BKV) infection occurs during childhood and remains latent in the urinary tract. The virus is reactivated in immunosuppressed patients, particularly in those with cellular immunity deficiency, allowing its detection in urine and blood. Nephropathy caused by the virus in renal transplantation recipients may lead to graft failure. The purpose of this study is to know the prevalence of BKV variables in renal transplantation recipients and to evaluate their clinical evolution through molecular methods of "in house" development...
March 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29464201/prediction-of-early-bk-virus-infection-in-kidney-transplant-recipients-by-the-number-of-cells-with-intranuclear-inclusion-bodies-decoy-cells
#8
Yoshiteru Yamada, Tomohiro Tsuchiya, Isao Inagaki, Mitsuru Seishima, Takashi Deguchi
Background: BK virus (BKV) is the cause of nephropathy. Because BKV nephropathy can progress to graft loss, early diagnosis of BKV infection is very important. In this study, we aimed to investigate the utility of quantifying cells with intranuclear inclusion bodies (decoy cells) in urinary sediment for the screening and monitoring of BKV infection in renal transplant recipients at our hospital. Methods: This was a retrospective single-center study. Urine sediment examination was performed at each outpatient visit, and the number of decoy cells was measured in the whole microscopic field...
February 2018: Transplantation Direct
https://www.readbyqxmd.com/read/29315820/de-novo-donor-specific-antibody-following-bk-nephropathy-the-incidence-and-association-with-antibody-mediated-rejection
#9
Wisit Cheungpasitporn, Walter K Kremers, Elizabeth Lorenz, Hatem Amer, Fernando G Cosio, Mark D Stegall, Manish J Gandhi, Carrie A Schinstock
BACKGROUND AND OBJECTIVES: The risk of de novo donor-specific antibody (dnDSA) development following BK viremia (BKV) or nephropathy (BKN) after kidney transplant remains unclear. We aimed to evaluate the relationships among dnDSA, BKV (BK blood PCR > 15 000 copies), BKN, antibody-mediated rejection (AMR), and allograft loss. PATIENTS AND METHODS: We performed a retrospective cohort study of 904 solitary kidney transplant recipients transplanted between 10/2007 and 5/2014...
March 2018: Clinical Transplantation
https://www.readbyqxmd.com/read/29312862/polyoma-virus-nephropathy-in-kidney-transplantation
#10
REVIEW
Jacob Rw Scadden, Adnan Sharif, Kassi Skordilis, Richard Borrows
BK virus (BKV) is a polyomavirus that is able to cause renal dysfunction in transplanted grafts via BK virus-associated nephritis (BKVAN). This condition was mis-diagnosed in the past due to clinical and histopthological similarities with acute rejection. Due to the prevalence of the virus in the population, it is an important pathogen in this context, and so it is important to understand how this virus functions and its' relationship with the pathogenesis of BKVN. Screening for BKV often reveals viruria and/or viremia, which then manifests as BKVN, which can be asymptomatic or result in clinical features namely renal dysfunction...
December 24, 2017: World Journal of Transplantation
https://www.readbyqxmd.com/read/29222360/antiviral-treatment-of-bk-virus-viremia-after-kidney-transplantation
#11
REVIEW
Andrew D Santeusanio, Benjamin E Lukens, Judy Eun
PURPOSE: The various antiviral treatment options in the management of BK virus (BKV) viremia and BKV-associated nephropathy (BKVAN) are reviewed. SUMMARY: Review of the PubMed database from 1990 to 2016 for all English language case series, cohort studies, and randomized controlled trials detailing antiviral treatment of BKV viremia or BKVAN in kidney transplant recipients returned only 16 published reports. The majority of these reports were based on small case series or protocol-based cohort studies, with no prospective head-to-head data and only modest benefit reported for cidofovir, leflunomide, i...
December 15, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/29156086/impact-of-low-level-bk-polyomavirus-viremia-on-intermediate-term-renal-allograft-function
#12
Johannes Korth, Marek Widera, Sebastian Dolff, Hana Guberina, Anja Bienholz, Alexandra Brinkhoff, Olympia Evdoxia Anastasiou, Andreas Kribben, Ulf Dittmer, Jens Verheyen, Benjamin Wilde, Oliver Witzke
BACKGROUND: BK polyomavirus (BKPyV)-associated nephropathy (PyVAN) is a significant cause of premature renal transplant failure. High-level BKPyV viremia is predictive for PyVAN; however, low-level BKPyV viremia does not necessarily exclude the presence of PyVAN. As data are limited regarding whether or not low-level BKPyV viremia has an effect on intermediate-term graft outcome, this study analyzes the impact of low-level BKPyV viremia on intermediate-term graft function and outcome compared with high-level viremia and non-viremic patients...
February 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29104861/graft-loss-among-renal-transplant-recipients-with-early-reduction-of-immunosuppression-for-bk-viremia
#13
Marwan M Azar, Roland Assi, Aziz K Valika, David B Banach, Isaac E Hall, Marie-Louise Landry, Maricar F Malinis
AIM: To review the incidence of graft loss and acute rejection among renal transplant recipients with early reduction of immunosuppression for BK viremia. METHODS: We performed a retrospective analysis of consecutive de-novo kidney-only transplants from January 2009 to December 2012 to evaluate the incidence of Polyoma-virus associated nephropathy (PyVAN). Recipient plasma was screened for BKV DNA via quantitative polymerase chain reaction (PCR) at months 1, 3, 6, 9 and 12 post-transplant and on worsening graft function...
October 24, 2017: World Journal of Transplantation
https://www.readbyqxmd.com/read/29042457/neutralizing-antibody-mediated-response-and-risk-of-bk-virus-associated-nephropathy
#14
Morgane Solis, Aurélie Velay, Raphaël Porcher, Pilar Domingo-Calap, Eric Soulier, Mélanie Joly, Mariam Meddeb, Wallys Kack-Kack, Bruno Moulin, Siamak Bahram, Françoise Stoll-Keller, Heidi Barth, Sophie Caillard, Samira Fafi-Kremer
BK virus-associated nephropathy (BKVAN) causes renal allograft dysfunction. The current management of BKVAN relies on pre-emptive adaptation of immunosuppression according to viral load monitoring. However, this empiric strategy is not always successful. Therefore, pretransplant predictive markers are needed. In a prospective longitudinal study, we enrolled 168 kidney transplant recipients and 69 matched donors. To assess the value of BKV genotype-specific neutralizing antibody (NAb) titers as a predictive marker for BKV replication, we measured BKV DNA load and NAb titers at transplant and followed patients for 24 months...
January 2018: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/29020348/kinetics-of-double-stranded-dna-viremia-after-allogeneic-hematopoietic-cell-transplantation
#15
Joshua A Hill, Bryan T Mayer, Hu Xie, Wendy M Leisenring, Meei-Li Huang, Terry Stevens-Ayers, Filippo Milano, Colleen Delaney, Keith R Jerome, Danielle M Zerr, Garrett Nichols, Michael Boeckh, Joshua T Schiffer
Background: Improved understanding of double-stranded DNA (dsDNA) virus kinetics after hematopoietic cell transplantation (HCT) would facilitate development of therapeutic strategies. Methods: We tested weekly plasma samples from 404 patients through day 100 after allogeneic HCT for cytomegalovirus (CMV), human herpesvirus (HHV) 6A and 6B, BK polyomavirus (BKV), adenovirus (AdV), and Epstein-Barr virus (EBV) using quantitative polymerase chain reaction. Episodes lasting ≤1 week were defined as blips and >1 week as persistent...
January 18, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28923623/mycophenolate-mofetil-withdrawal-with-conversion-to-everolimus-to-treat-bk-virus-infection-in-kidney-transplant-recipients
#16
D Wojciechowski, S Chandran, A Webber, R Hirose, F Vincenti
BACKGROUND: BK virus (BKV) is a significant post-transplant infection. Mammalian target of rapamycin inhibitors (mTORis) reduce BKV large T antigen expression in vitro and are associated with lower rates of BKV infection when used as de novo immunosuppression in clinical studies. METHODS: We performed a prospective, single-center, randomized, open label pilot trial to evaluate the impact of mycophenolate mofetil (MMF) withdrawal with conversion to the mTORi everolimus versus a 50% reduction of the MMF dose for the treatment of BKV infection after kidney transplantation...
October 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28921709/kidney-allograft-failure-in-the-steroid-free-immunosuppression-era-a-matched-case-control-study
#17
Mohamad M Alkadi, Jim Kim, Meredith J Aull, Joseph E Schwartz, John R Lee, Anthony Watkins, Jun B Lee, Darshana M Dadhania, Surya V Seshan, David Serur, Sandip Kapur, Manikkam Suthanthiran, Choli Hartono, Thangamani Muthukumar
We studied the causes and predictors of death-censored kidney allograft failure among 1670 kidney recipients transplanted at our center in the corticosteroid-free maintenance immunosuppression era. As of January 1, 2012, we identified 137 recipients with allograft failure; 130 of them (cases) were matched 1-1 for recipient age, calendar year of transplant, and donor type with 130 recipients with functioning grafts (controls). Median time to allograft failure was 29 months (interquartile range: 18-51). Physician-validated and biopsy-confirmed categories of allograft failure were as follows: acute rejection (21%), glomerular disease (19%), transplant glomerulopathy (13%), interstitial fibrosis tubular atrophy (10%), and polyomavirus-associated nephropathy (7%)...
November 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/28915452/bk-virus-replication-in-renal-transplant-recipients-analysis-of-potential-risk-factors-may-contribute-in-reactivation
#18
Mohammad Shenagari, Ali Monfared, Hadise Eghtedari, Aydin Pourkazemi, Tolou Hasandokht, Masoud Khosravi, Babak Asharfkhani
BACKGROUND: Considering the increasing problem of BK virus infection during post renal transplant surveillance, it is necessary to distinguish the main risk factors leading to reactivation of latent BK virus. Up to now, some probable risk factors have been investigated in some studies, but the results have been confusing and contradictory. OBJECTIVES: The goal of the present study was to determine the frequency and potential risk factors that may play a role in BK polyomavirus reactivation and nephropathy...
November 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28834032/bk-polyomavirus-infection-after-renal-transplantation-surveillance-in-a-resource-challenged-setting
#19
Soumita Bagchi, Vikraman Gopalakrishnan, Sandeep Kumar Srivastava, Ashish Upadhayay, Geetika Singh, Dipankar Bhowmik, Sandeep Mahajan, Amit Dinda, Sanjay Kumar Agarwal
BACKGROUND: There is a paucity of data available about BK polyomavirus (BKPyV) infection after renal transplantation (RTX) in resource-limited countries with a predominantly living-donor, ABO-compatible RTX program. We aimed to assess BKPyV infection in such patients in a public hospital in India. METHODS: We prospectively evaluated plasma BKPyV replication in 62 patients at 1, 3, 6, 9, and 12 months after RTX. Sustained significant BK viremia (SSBKV) was defined as significant viremia (≥10 000 copies/mL) detected ≥2 times, and BKPyV-associated nephropathy (BKVAN) as histologic changes of BKVAN with BK viremia with/without graft dysfunction...
December 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/28665480/simultaneous-pancreas-kidney-transplant-recipients-are-predisposed-to-tissue-invasive-cytomegalovirus-disease-and-concomitant-infectious-complications
#20
Thomas Schachtner, Marina Zaks, Natalie M Otto, Andreas Kahl, Petra Reinke
BACKGROUND: Infections have increased in simultaneous pancreas/kidney transplant recipients (SPKTRs) with cytomegalovirus (CMV) infection being the most important viral infection with adverse impact on patient and allograft outcomes. METHODS: We studied all primary SPKTRs and deceased-donor kidney transplant recipients (KTRs) between 2008 and 2015 for the development of CMV infection. A total of 21/62 SPKTRs (33.9%) and 90/335 KTRs (26.9%) were diagnosed with CMV infection...
June 30, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
keyword
keyword
18260
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"